256 related articles for article (PubMed ID: 28183292)
21. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
Stacchiotti S; Negri T; Palassini E; Conca E; Gronchi A; Morosi C; Messina A; Pastorino U; Pierotti MA; Casali PG; Pilotti S
Mol Cancer Ther; 2010 May; 9(5):1286-97. PubMed ID: 20457621
[TBL] [Abstract][Full Text] [Related]
22. Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group.
Hettmer S; Dachy G; Seitz G; Agaimy A; Duncan C; Jongmans M; Hirsch S; Kventsel I; Kordes U; de Krijger RR; Metzler M; Michaeli O; Nemes K; Poluha A; Ripperger T; Russo A; Smetsers S; Sparber-Sauer M; Stutz E; Bourdeaut F; Kratz CP; Demoulin JB
Fam Cancer; 2021 Oct; 20(4):327-336. PubMed ID: 32888134
[TBL] [Abstract][Full Text] [Related]
23. Infantile myofibromatosis: report on a family with autosomal dominant inheritance and variable penetrance.
Kulkarni K; Desai S; Grundy P; Sergi C
J Pediatr Surg; 2012 Dec; 47(12):2312-5. PubMed ID: 23217896
[TBL] [Abstract][Full Text] [Related]
24. Vincristine and Dactinomycin in Infantile Myofibromatosis With a Review of Treatment Options.
Weaver MS; Navid F; Huppmann A; Meany H; Angiolillo A
J Pediatr Hematol Oncol; 2015 Apr; 37(3):237-41. PubMed ID: 25389917
[TBL] [Abstract][Full Text] [Related]
25. Aggressive infantile myofibromatosis with intestinal involvement.
Römer T; Wagner N; Braunschweig T; Meyer R; Elbracht M; Kontny U; Moser O
Mol Cell Pediatr; 2021 Jun; 8(1):7. PubMed ID: 34132909
[TBL] [Abstract][Full Text] [Related]
26. Exome sequencing identifies a novel homozygous variant in NDRG4 in a family with infantile myofibromatosis.
Linhares ND; Freire MC; Cardenas RG; Pena HB; Bahia M; Pena SD
Eur J Med Genet; 2014; 57(11-12):643-8. PubMed ID: 25241110
[TBL] [Abstract][Full Text] [Related]
27. Brief report: successful therapy of a patient with infantile generalized myofibromatosis.
Day M; Edwards AO; Weinberg A; Leavey PJ
Med Pediatr Oncol; 2002 May; 38(5):371-3. PubMed ID: 11979466
[No Abstract] [Full Text] [Related]
28. Mutations in PDGFRB and NOTCH3 are the first genetic causes identified for autosomal dominant infantile myofibromatosis.
Lee JW
Clin Genet; 2013 Oct; 84(4):340-1. PubMed ID: 23865785
[No Abstract] [Full Text] [Related]
29. [Autosomal dominant (familial) infantile myofibromatosis: The causative role of mutations in PDGFRB and NOTCH3].
Dereure O
Ann Dermatol Venereol; 2013 Dec; 140(12):833-4. PubMed ID: 24315235
[No Abstract] [Full Text] [Related]
30. Generalized Infantile Myofibromatosis with Extensive Small Bowel Involvement in a Neonate.
Schubert JP; Wößmann W; Königs I; Clauditz T; Kordes U; Reinshagen K
Z Geburtshilfe Neonatol; 2023 Jun; 227(3):231-235. PubMed ID: 36921614
[TBL] [Abstract][Full Text] [Related]
31. A tyrosine kinase-activating variant Asn666Ser in PDGFRB causes a progeria-like condition in the severe end of Penttinen syndrome.
Bredrup C; Stokowy T; McGaughran J; Lee S; Sapkota D; Cristea I; Xu L; Tveit KS; Høvding G; Steen VM; Rødahl E; Bruland O; Houge G
Eur J Hum Genet; 2019 Apr; 27(4):574-581. PubMed ID: 30573803
[TBL] [Abstract][Full Text] [Related]
32. Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapy.
Wenger TL; Bly RA; Wu N; Albert CM; Park J; Shieh J; Chenbhanich J; Heike CL; Adam MP; Chang I; Sun A; Miller DE; Beck AE; Gupta D; Boos MD; Zackai EH; Everman D; Ganapathi S; Wilson M; Christodoulou J; Zarate YA; Curry C; Li D; Guimier A; Amiel J; Hakonarson H; Webster R; Bhoj EJ; Perkins JA; Dahl JP; Dobyns WB
Am J Med Genet A; 2020 Jul; 182(7):1576-1591. PubMed ID: 32500973
[TBL] [Abstract][Full Text] [Related]
33. Diverse presentation and tailored treatment of infantile myofibromatosis: A single-center experience.
Manisterski M; Benish M; Levin D; Shiran SI; Sher O; Gortzak Y; Elhasid R
Pediatr Blood Cancer; 2021 Feb; 68(2):e28769. PubMed ID: 33063933
[TBL] [Abstract][Full Text] [Related]
34. Infantile myofibromatosis.
Larralde M; Ferrari B; Martinez JP; Barbieri MAF; Méndez JH; Casas J
An Bras Dermatol; 2017; 92(6):854-857. PubMed ID: 29364448
[TBL] [Abstract][Full Text] [Related]
35. Risk-adapted therapy for infantile myofibromatosis in children.
Levine E; Fréneaux P; Schleiermacher G; Brisse H; Pannier S; Teissier N; Mesples B; Orbach D
Pediatr Blood Cancer; 2012 Jul; 59(1):115-20. PubMed ID: 22038698
[TBL] [Abstract][Full Text] [Related]
36. Novel Oncogenic
Elsbernd A; Boulouadnine B; Ahmed A; Farooqi M; Sandritter T; Shakhnovich V; Blanding D; Demoulin JB; Thompson J
JCO Precis Oncol; 2022 Oct; 6():e2200250. PubMed ID: 36201717
[No Abstract] [Full Text] [Related]
37. Remission of infantile generalized myofibromatosis after interferon alpha therapy.
Auriti C; Kieran MW; Deb G; Devito R; Pasquini L; Danhaive O
J Pediatr Hematol Oncol; 2008 Feb; 30(2):179-81. PubMed ID: 18376275
[TBL] [Abstract][Full Text] [Related]
38. Expansion of the phenotype of Kosaki overgrowth syndrome.
Minatogawa M; Takenouchi T; Tsuyusaki Y; Iwasaki F; Uehara T; Kurosawa K; Kosaki K; Curry CJ
Am J Med Genet A; 2017 Sep; 173(9):2422-2427. PubMed ID: 28639748
[TBL] [Abstract][Full Text] [Related]
39. [Chemotherapy in fibromatoses of childhood and adolescence: results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group (ICG-AIEOP)].
Pilz T; Pilgrim TB; Bisogno G; Knietig R; Koscielniak E; Carli M; Treuner J
Klin Padiatr; 1999; 211(4):291-5. PubMed ID: 10472564
[TBL] [Abstract][Full Text] [Related]
40. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis.
Barry KK; Schienda J; Morrow JJ; Al-Ibraheemi A; Balkin DM; Church AJ; Eng W; Janeway KA; Kamihara J; Liang MG
Pediatr Blood Cancer; 2023 Jun; 70(6):e30262. PubMed ID: 36861440
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
